ELSA CRUZ: Open Payments
NPI 1861524159 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,115 in 153 payments from 19 companies in 2025. Trend: 2023 $1,312 · 2024 $2,313 · 2025 $4,115
Food & beverage: $4,115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $1,010 |
| Otsuka America Pharmaceutical, Inc. | 21 | $713 |
| E.R. Squibb & Sons, L.L.C. | 7 | $430 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $381 |
| Alkermes, Inc. | 14 | $293 |
| Lundbeck LLC | 14 | $256 |
| Vanda Pharmaceuticals Inc. | 10 | $183 |
| Noven Therapeutics, LLC | 10 | $170 |
| Neurocrine BioSciences, Inc. | 3 | $163 |
| Tris Pharma Inc | 6 | $135 |
Products named: VRAYLAR, REXULTI, COBENFY, CAPLYTA, ARISTADA, FANAPT, INGREZZA, Secuado.
Industry payments across CA — which companies pay providers there.
